Concord Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE858L01010
  • NSEID:
  • BSEID: 538965
INR
68.51
-1.28 (-1.83%)
BSENSE

Nov 20

BSE+NSE Vol: 1.23 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 605306,
    "name": "Concord Drugs",
    "stock_name": "Concord Drugs",
    "full_name": "Concord Drugs Ltd",
    "name_url": "stocks-analysis/concord-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "68.51",
    "chg": -1.28,
    "chgp": "-1.83%",
    "dir": -1,
    "prev_price": "69.79",
    "mcapval": "90.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 538965,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE858L01010",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "1.23 k",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/concord-drugs-605306-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Concord Drugs Ltd is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-by-marketsmojo-4269267",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/ConcordDrugsLtd_mojoScore_4269267.png",
        "date": "2026-11-20 10:10:35",
        "description": "Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 November 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Concord Drugs Ltd Valuation Shifts to Attractive Amid Mixed Market Returns",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/concord-drugs-ltd-valuation-shifts-to-attractive-amid-mixed-market-returns-4262970",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/ConcordDrugsLtd_valuationdot_4262970.png",
        "date": "2026-11-16 08:00:59",
        "description": "Concord Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters improve notably, shifting from very attractive to attractive. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more compelling entry point relative to peers and historical averages, warranting a closer examination of its price attractiveness and underlying fundamentals."
      },
      {
        "title": "Concord Drugs Gains 0.73%: Quarterly Surge Amid Mixed Market Returns",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/concord-drugs-gains-073-quarterly-surge-amid-mixed-market-returns-4261980",
        "imagepath": "",
        "date": "2026-11-14 16:04:13",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Nov 09:</strong> Stock opens at Rs.72.72 with a 2.19% gain</p>\n                    <p><strong>Nov 11:</strong> Price dips to Rs.71.11 amid lower volume</p>\n                    <p><strong>Nov 12:</strong> Rebounds to Rs.72.95 with 2.59% gain</p>\n                    <p><strong>Nov 13:</strong> Quarterly results released; closes at Rs.71.68 (-1.74%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.71.16</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.71.68</div><div class=\"stat-change ..."
      },
      {
        "title": "Concord Drugs Ltd Reports Very Positive Quarterly Financial Performance Amid Mixed Long-Term Returns",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/concord-drugs-ltd-reports-very-positive-quarterly-financial-performance-amid-mixed-long-term-returns-4260855",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/ConcordDrugsLtd_fintrenddot_4260855.png",
        "date": "2026-11-13 11:00:59",
        "description": "Concord Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has delivered a very positive financial performance for the quarter ended September 2026, marked by robust revenue growth and margin expansion. Despite this, the company’s stock has experienced mixed returns relative to broader market indices, reflecting ongoing challenges and investor caution."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-by-marketsmojo-4238636",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ConcordDrugsLtd_mojoScore_4238636.png",
        "date": "2026-10-26 10:10:39",
        "description": "Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Concord Drugs Ltd Falls 8.48%: Valuation Shift and Technical Upgrade Mark a Volatile Week",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/concord-drugs-ltd-falls-848-valuation-shift-and-technical-upgrade-mark-a-volatile-week-4221417",
        "imagepath": "",
        "date": "2026-10-10 16:05:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>5 Oct:</strong> Valuation upgraded to Very Attractive amid market volatility</p>\n                    <p><strong>6 Oct:</strong> Investment rating upgraded from Sell to Hold on improved technicals</p>\n                    <p><strong>9 Oct:</strong> Week closes at Rs.70.40, down 8.48%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.76.92</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.70.40</div><div class=\"stat-change negative\">-8.48%</div></div>\n                    <div class=\"stat-..."
      },
      {
        "title": "Concord Drugs Ltd Valuation Shifts to Very Attractive Amid Market Volatility",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/concord-drugs-ltd-valuation-shifts-to-very-attractive-amid-market-volatility-4213645",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ConcordDrugsLtd_valuationdot_4213645.png",
        "date": "2026-10-05 08:01:58",
        "description": "Concord Drugs Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating, despite a mixed performance relative to the broader market. This change reflects evolving investor sentiment and a reassessment of the company’s price multiples compared to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Concord Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/concord-drugs-ltd-downgraded-to-sell-amid-mixed-financial-and-technical-signals-4210564",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ConcordDrugsLtd_mojoScore_4210564.png",
        "date": "2026-10-01 08:09:44",
        "description": "Concord Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 30 Sep 2026. This revision reflects a complex interplay of deteriorating technical indicators, modest financial trends, valuation considerations, and overall quality assessments, despite the company’s recent impressive quarterly earnings."
      },
      {
        "title": "Concord Drugs Ltd Upgraded to Hold by MarketsMOJO on Technical and Financial Improvements",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/concord-drugs-ltd-upgraded-to-hold-by-marketsmojo-on-technical-and-financial-improvements-4203033",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/ConcordDrugsLtd_mojoScore_4203033.png",
        "date": "2026-09-24 08:08:38",
        "description": "Concord Drugs Ltd has seen its investment rating upgraded from Sell to Hold, reflecting notable improvements in technical indicators and robust quarterly financial performance. The pharmaceutical company’s recent results, combined with a stabilising technical trend and attractive valuation metrics, have prompted analysts to revise their outlook, signalling cautious optimism amid mixed long-term fundamentals."
      }
    ],
    "total": 43,
    "sid": "605306",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/concord-drugs-605306"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "14-Nov-2026",
      "details": "NewsPaper publication of Financial results for quarter ended 30th Sep2026.",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For Quarter Ending 30Th Sep 2026.",
      "datetime": "12-Nov-2026",
      "details": "Board has approved and considered financial results for quarter ending 30th Sep 2026.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting For Quarterly Results",
      "datetime": "12-Nov-2026",
      "details": "Board has Considered and approved quarterly results for 30th Sep2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

14-Nov-2026 | Source : BSE

NewsPaper publication of Financial results for quarter ended 30th Sep2026.

Financial Results For Quarter Ending 30Th Sep 2026.

12-Nov-2026 | Source : BSE

Board has approved and considered financial results for quarter ending 30th Sep 2026.

Board Meeting Outcome for Outcome Of Board Meeting For Quarterly Results

12-Nov-2026 | Source : BSE

Board has Considered and approved quarterly results for 30th Sep2026.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available